Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A comprehensive review of FDA Adverse Event Reporting System (FAERS) safety signals for Prolia (denosumab), including rebound vertebral fractures, atypical femoral fractures, hypocalcemia, and osteonecrosis of the jaw.
Read clinical reviewA detailed regulatory timeline of denosumab (Prolia/Xgeva) from initial FDA approval through post-market safety updates, label expansions, and biosimilar developments.
Read clinical reviewComplete regulatory overview of denosumab (Prolia/Xgeva) covering FDA approval history, EMA authorization, boxed warning additions, REMS requirements, and global post-market surveillance findings.
Read clinical reviewA comprehensive review of every major FDA label change for Prolia (denosumab) from 2020 through 2026, including the rebound fracture warning, hypocalcemia updates, and post-market surveillance findings.
Read clinical reviewA side-by-side comparison of how the FDA and EMA regulate denosumab (Prolia/Xgeva), including approval timelines, label differences, post-market safety signals, and discontinuation guidance.
Read clinical reviewA clinical review of denosumab (Prolia/Xgeva) regulatory history, current FDA label, post-market safety signals, biosimilar pipeline, and next-generation anti-resorptive therapies in development.
Read clinical reviewA detailed review of the legal, patent, and regulatory challenges surrounding Prolia (denosumab), including FDA approval history, biosimilar competition, safety labeling updates, and post-market litigation.
Read clinical review